173 related articles for article (PubMed ID: 20550533)
81. Altered systemic cortisol metabolism in bipolar disorder and schizophrenia spectrum disorders.
Steen NE; Methlie P; Lorentzen S; Dieset I; Aas M; Nerhus M; Haram M; Agartz I; Melle I; Berg JP; Andreassen OA
J Psychiatr Res; 2014 May; 52():57-62. PubMed ID: 24534618
[TBL] [Abstract][Full Text] [Related]
82. Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients.
Hoshiro M; Ohno Y; Masaki H; Iwase H; Aoki N
Clin Endocrinol (Oxf); 2006 Jan; 64(1):37-45. PubMed ID: 16402926
[TBL] [Abstract][Full Text] [Related]
83. Low-renin, low-aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child.
Fiselier TJ; Otten BJ; Monnens LA; Honour JW; van Munster PJ
Horm Res; 1982; 16(2):107-14. PubMed ID: 7049881
[TBL] [Abstract][Full Text] [Related]
84. Growth hormone replacement inhibits renal and hepatic 11 beta-hydroxysteroid dehydrogenases in ACTH-deficient patients.
Walker BR; Andrew R; MacLeod KM; Padfield PL
Clin Endocrinol (Oxf); 1998 Aug; 49(2):257-63. PubMed ID: 9828916
[TBL] [Abstract][Full Text] [Related]
85. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation.
Papadimitriou M; Vyzantiadis A; Milionis A; Memmos D; Metaxas P
Life Support Syst; 1983; 1(3):197-205. PubMed ID: 6433115
[TBL] [Abstract][Full Text] [Related]
86. The dissociation of renin and aldosterone during critical illness.
Findling JW; Waters VO; Raff H
J Clin Endocrinol Metab; 1987 Mar; 64(3):592-5. PubMed ID: 3029157
[TBL] [Abstract][Full Text] [Related]
87. 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione.
Swart AC; Schloms L; Storbeck KH; Bloem LM; Toit Td; Quanson JL; Rainey WE; Swart P
J Steroid Biochem Mol Biol; 2013 Nov; 138():132-42. PubMed ID: 23685396
[TBL] [Abstract][Full Text] [Related]
88. New findings in apparent mineralocorticoid excess.
DiMartino-Nardi J; Stoner E; Martin K; Balfe JW; Jose PA; New MI
Clin Endocrinol (Oxf); 1987 Jul; 27(1):49-62. PubMed ID: 2820623
[TBL] [Abstract][Full Text] [Related]
89. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.
Andrews RC; Herlihy O; Livingstone DE; Andrew R; Walker BR
J Clin Endocrinol Metab; 2002 Dec; 87(12):5587-93. PubMed ID: 12466357
[TBL] [Abstract][Full Text] [Related]
90. Plasma corticosteroid concentrations during spironolactone administration: evidence for adrenal biosynthetic blockade in man.
Tuck ML; Sowers JR; Fittingoff DB; Fisher JS; Berg GJ; Asp ND; Mayes DM
J Clin Endocrinol Metab; 1981 Jun; 52(6):1057-61. PubMed ID: 6262360
[TBL] [Abstract][Full Text] [Related]
91. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
92. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.
Nowak KL; Gitomer B; Farmer-Bailey H; Wang W; Malaczewski M; Klawitter J; You Z; George D; Patel N; Jovanovich A; Chonchol M
Am J Kidney Dis; 2019 Aug; 74(2):213-223. PubMed ID: 30803706
[TBL] [Abstract][Full Text] [Related]
93. Aldosterone Contributes to Sympathoexcitation in Renovascular Hypertension.
Lincevicius GS; Shimoura CG; Nishi EE; Perry JC; Casarini DE; Gomes GN; Bergamaschi CT; Campos RR
Am J Hypertens; 2015 Sep; 28(9):1083-90. PubMed ID: 25628418
[TBL] [Abstract][Full Text] [Related]
94. Role of 11beta-hydroxysteroid dehydrogenase 2 renal activity in potassium homeostasis in rats with chronic renal failure.
Yeyati NL; Altuna ME; Damasco MC; Mac Laughlin MA
Braz J Med Biol Res; 2010 Jan; 43(1):52-6. PubMed ID: 20027486
[TBL] [Abstract][Full Text] [Related]
95. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
Mahmud A; Feely J
Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
[TBL] [Abstract][Full Text] [Related]
96. Aldosterone excess and resistance to 24-h blood pressure control.
Pimenta E; Gaddam KK; Pratt-Ubunama MN; Nishizaka MK; Cofield SS; Oparil S; Calhoun DA
J Hypertens; 2007 Oct; 25(10):2131-7. PubMed ID: 17885558
[TBL] [Abstract][Full Text] [Related]
97. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
Bianchi S; Bigazzi R; Campese VM
Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
[TBL] [Abstract][Full Text] [Related]
98. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.
Sengul E; Sahin T; Sevin E; Yilmaz A
Ren Fail; 2009; 31(10):928-32. PubMed ID: 20030528
[TBL] [Abstract][Full Text] [Related]
99. Effect of physiological levels of atrial natriuretic peptide on hormone secretion: inhibition of angiotensin-induced aldosterone secretion and renin release in normal man.
Cuneo RC; Espiner EA; Nicholls MG; Yandle TG; Livesey JH
J Clin Endocrinol Metab; 1987 Oct; 65(4):765-72. PubMed ID: 2821056
[TBL] [Abstract][Full Text] [Related]
100. Lower Renal Function Is Associated With Derangement of 11-
Gant CM; Minovic I; Binnenmars H; de Vries L; Kema I; van Beek A; Navis G; Bakker S; Laverman GD
J Endocr Soc; 2018 Jul; 2(7):609-620. PubMed ID: 29942925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
